Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660

Article  PubMed  Google Scholar 

Walker AJ, Wedam S, Amiri-Kordestani L, Bloomquist E, Tang S et al (2016) FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 22:4968–4972. https://doi.org/10.1158/1078-0432.Ccr-16-0493

Article  CAS  PubMed  Google Scholar 

Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T et al (2015) FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 21:4760–4766. https://doi.org/10.1158/1078-0432.Ccr-15-1185

Article  CAS  PubMed  Google Scholar 

Diéras V, Harbeck N, Joy AA (2017) PALOMA-2: neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2–) first-line advanced breast cancer (ABC) receiving palbociclib + letrozole (P + L). Ann Oncol 28:291

Article  Google Scholar 

Iwata H, Im SA, Masuda N, Im YH, Inoue K et al (2017) PALOMA-3: phase III trial of fulvestrant with or without palbociclib in premenopausal and postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer that progressed on prior endocrine therapy-safety and efficacy in Asian patients. J Glob Oncol 3:289–303. https://doi.org/10.1200/jgo.2016.008318

Article  PubMed  PubMed Central  Google Scholar 

Inc, F. (2015) IBRANCE® (palbociclib): US prescribing information.

Asghar U, Witkiewicz AK, Turner NC, Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery 14:130–146. https://doi.org/10.1038/nrd4504

Article  CAS  PubMed  Google Scholar 

Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia. Cancer 100:228–237. https://doi.org/10.1002/cncr.11882

Article  PubMed  Google Scholar 

Xu B, Li H, Zhang Q, Sun W, Yu Y et al (2021) Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2− advanced breast cancer in Chinese women. Cancer Chemother Pharmacol 88:131–141. https://doi.org/10.1007/s00280-021-04263-9

Article  CAS  PubMed  Google Scholar 

Im SA, Mukai H, Park IH, Masuda N, Shimizu C et al (2019) Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: results from the phase III, randomized PALOMA-2 study. J Glob Oncol 5:1–19. https://doi.org/10.1200/JGO.18.00173

Article  CAS  PubMed  Google Scholar 

Zheng J, Yu Y, Durairaj C, Diéras V, Finn RS et al (2021) Impact of dose reduction on efficacy: implications of exposure–response analysis of palbociclib. Target Oncol 16:69–76. https://doi.org/10.1007/s11523-020-00771-5

Article  PubMed  Google Scholar 

Lee J, Park HS, Won HS, Yang JH, Lee HY et al (2021) Real-world clinical data of palbociclib in Asian metastatic breast cancer patients: experiences from eight institutions. Cancer Res Treat 53:409–423. https://doi.org/10.4143/crt.2020.451

Article  CAS  PubMed  Google Scholar 

Jacqmin P, Snoeck E, van Schaick EA, Gieschke R, Pillai P et al (2007) Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K–PD model. J Pharmacokinet Pharmacodyn 34:57–85. https://doi.org/10.1007/s10928-006-9035-z

Article  CAS  PubMed  Google Scholar 

Sun W, O’Dwyer PJ, Finn RS, Ruiz-Garcia A, Shapiro GI et al (2017) Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic–pharmacodynamic modeling and simulation approach. J Clin Pharmacol 57:1159–1173. https://doi.org/10.1002/jcph.902

Article  CAS  PubMed  Google Scholar 

Yanke Yu, D. W. (2019) Population pharmacokinetics and exposure–response of neutropenia: analyses in first-line patients with advanced breast cancer with palbociclib treatment. American College of Clinical Pharmacology Annual Meeting. Chicago, IL, USA

Yu Y, Sun W, Liu Y, Wang D (2022) Pharmacodynamic modeling of CDK4/6 inhibition-related biomarkers and the characterization of the relationship between biomarker response and progression-free survival in patients with advanced breast cancer. J Clin Pharmacol 62:376–384. https://doi.org/10.1002/jcph.1971

Article  CAS  PubMed  Google Scholar 

Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–4721. https://doi.org/10.1200/JCO.2002.02.140

Article  PubMed  Google Scholar 

van der Meer AF, Marcus MA, Touw DJ, Proost JH, Neef C (2011) Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation. Ther Drug Monit 33:133–146. https://doi.org/10.1097/FTD.0b013e31820f40f8

Article  PubMed  Google Scholar 

Spring LM, Wander SA, Andre F, Moy B, Turner NC et al (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395:817–827. https://doi.org/10.1016/S0140-6736(20)30165-3

Article  CAS  PubMed  Google Scholar 

Marouille AL, Petit E, Kaderbhaï C, Desmoulins I, Hennequin A et al (2021) Pharmacokinetic/pharmacodynamic model of neutropenia in real-life palbociclib-treated patients. Pharmaceutics 13:1708

Article  CAS  Google Scholar 

Royer B, Kaderbhai C, Fumet JD, Hennequin A, Desmoulins I et al (2021) Population pharmacokinetics of palbociclib in a real-world situation. Pharmaceuticals (Basel). https://doi.org/10.3390/ph14030181

Article  Google Scholar 

Wan Sun, D. W. (2014) A population pharmacokinetic analysis of palbociclib (PD-0332991) in patients with advanced cancer. European Society for Medical Oncology 2014 Congress

Jusko WJ, Ko HC (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56:406–419. https://doi.org/10.1038/clpt.1994.155

Article  CAS  PubMed  Google Scholar 

Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427–437. https://doi.org/10.1634/theoncologist.10-6-427

Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif